Literature DB >> 29703686

Risks and Benefits of Adjuvant Radiotherapy After Inguinal Lymphadenectomy in Node-positive Penile Cancer: A Systematic Review by the European Association of Urology Penile Cancer Guidelines Panel.

Richard Robinson1, Lorenzo Marconi2, Ekelechi MacPepple3, Oliver W Hakenberg4, Nick Watkin5, Yuhong Yuan6, Thomas Lam7, Steven MacLennan8, Temitope E Adewuyi9, Alberto Coscione10, Suks S Minhas11, Eva M Compérat12, Andrea Necchi13.   

Abstract

CONTEXT: Management of men with penile squamous cell carcinoma (PSCC) who have high-risk features following radical inguinal lymphadenectomy (ILND) remains controversial. European Association of Urology guidelines state that adjuvant inguinal radiotherapy (AIRT) is "not generally recommended". Despite this, many centres continue to offer AIRT to a subset of men.
OBJECTIVE: To undertake a systematic review of the evidence on AIRT in node-positive men with PSCC. EVIDENCE ACQUISITION: A systematic review was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, with no language or date restriction. Inclusion criteria were men with PSCC, pathologically staged inguinal node positive after ILND. The intervention included ILND with AIRT compared with ILND alone. Primary outcomes were relapse-free survival and toxicity. Risk of bias assessment was undertaken. EVIDENCE SYNTHESIS: A total of 913 abstracts were identified and screened independently by two reviewers. Seven studies were eligible for inclusion: six full-text manuscripts and one conference abstract. All were retrospective series and at a high risk of bias. The selected studies included 1605 men. Indications for AIRT varied but were typically involvement of two or more inguinal nodes or extranodal extension. Regional recurrence rate following AIRT was reported at 10-91.7%. Only one study reported on toxicity. Two studies compared recurrence and survival between men who received and who did not receive AIRT, with no significant difference (p>0.05).
CONCLUSIONS: The evidence indicates that men treated with AIRT do not gain benefit with respect to relapse or survival. Uncertainty remains due to the retrospective nature and high risks of bias across the evidence. Given the lack of evidence supporting AIRT, it cannot be recommended for routine practice. PATIENT
SUMMARY: Men with penile cancer who have involvement of the inguinal lymph nodes are at a high risk of cancer recurrence and death. We reviewed the literature to see if radiation treatment after removal of the nodes provided benefit. We did not find any good-quality evidence supporting this treatment, and hence it cannot be recommended.
Copyright © 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adjuvant radiotherapy; Lymph nodes; Penile cancer

Mesh:

Year:  2018        PMID: 29703686     DOI: 10.1016/j.eururo.2018.04.003

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  17 in total

1.  Radiotherapy plus chemotherapy versus chemotherapy alone in penile cancer patients with extracapsular nodal extension after inguinal lymph node surgery: a multi-institutional study.

Authors:  Zai-Shang Li; Xue-Ying Li; Bin Wang; Peng Chen; Xiang Li; Ornellas Antonio Augusto; Zi-Ke Qin; Zhuo-Wei Liu; Yong-Hong Li; Hui Han; Fang-Jian Zhou
Journal:  World J Urol       Date:  2020-04-17       Impact factor: 4.226

2.  National Practice Patterns and Overall Survival After Adjuvant Radiotherapy Following Radical Cystectomy for Urothelial Bladder Cancer in the USA, 2004-2013.

Authors:  Zhoobin H Bateni; Shane M Pearce; Daniel Zainfeld; Leslie Ballas; Hooman Djaladat; Anne K Schuckman; Siamak Daneshmand
Journal:  Eur Urol Oncol       Date:  2018-12-19

3.  Long-term outcomes for penile cancer patients presenting with advanced N3 disease requiring a myocutaneous flap reconstruction or primary closure-a retrospective single centre study.

Authors:  Hussain M Alnajjar; Findlay MacAskill; Michelle Christodoulidou; Ash Mosahebi; Clare Akers; Raj Nigam; Peter Malone; David Ralph; Anita Mitra; Asif Muneer
Journal:  Transl Androl Urol       Date:  2019-03

4.  Primary Penile Cancer: The Role of Adjuvant Radiation Therapy in the Management of Extranodal Extension in Lymph Nodes.

Authors:  Peter A S Johnstone; David Boulware; Rosa Djajadiningrat; Sarah Ottenhof; Andrea Necchi; Mario Catanzaro; Dingwei Ye; Yao Zhu; Nicola Nicolai; Simon Horenblas; Philippe E Spiess
Journal:  Eur Urol Focus       Date:  2018-10-14

Review 5.  Progress on Management of Penile Cancer in 2020.

Authors:  Mohamed E Ahmed; Mahmoud I Khalil; Mohamed H Kamel; R Jeffrey Karnes; Philippe E Spiess
Journal:  Curr Treat Options Oncol       Date:  2020-11-23

Review 6.  Recent advances in the management of penile cancer.

Authors:  Maximilian J Johnston; Raj Nigam
Journal:  F1000Res       Date:  2019-04-26

7.  Adding radiotherapy based on chemotherapy can improve cancer-specific survival in N3 penile cancer: a SEER-based study.

Authors:  Wei-Kang Chen; Zhi-Gang Wu
Journal:  Transl Androl Urol       Date:  2020-12

8.  Intrinsic radiosensitivity, genomic-based radiation dose and patterns of failure of penile cancer in response to adjuvant radiation therapy.

Authors:  Zhigang Yuan; G Daniel Grass; Mounsif Azizi; Kamran A Ahmed; G Sean J Yoder; Eric A Welsh; William J Fulp; Jasreman Dhillon; Javier F Torres-Roca; Anna R Giuliano; Philippe E Spiess; Peter A Johnstone
Journal:  Rep Pract Oncol Radiother       Date:  2019-11-01

Review 9.  Tumor Microenvironment in Penile Cancer.

Authors:  Matthias Walter
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

Review 10.  Penile cancer: a Brazilian consensus statement for low- and middle-income countries.

Authors:  Andrey Soares; Icaro Thiago de Carvalho; Aluízio Gonçalves da Fonseca; Antonio Machado Alencar; Carlos Heli Bezerra Leite; Diogo Assed Bastos; João Paulo Holanda Soares; Katia Ramos Moreira Leite; Mário Ronalsa Brandão Filho; Ronald Wagner Pereira Coelho; Sandro Roberto de A Cavallero; Stênio de Cassio Zequi; José de Ribamar Rodrigues Calixto
Journal:  J Cancer Res Clin Oncol       Date:  2020-10-26       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.